Skip to content
DataLookout
Menu

NCT06978647

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from May 19, 2026 to May 19, 2027
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 1 of 6 entries
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of Treatment-Emergent Adverse Events
Timeframe: The efficacy endpoint evaluation for 2, 4, 8, 12 weeks, AEs observation will be follow-up for 24 weeks. The observation period is extended to 52 weeks.

Secondary (6)

Efficacy Evaluation in relapsed/refractory autoimmune diseases
Maximum Plasma Concentration of YTS109 (Cmax)
Area Under the Plasma Concentration-Time Curve (AUC) of YTS109
Time to Reach Maximum Plasma Concentration (Tmax) of YTS109
PD Biomarker Level Change (Cytokines Concentration)
Show 1 moreShow less
PD Biomarker Level Change (B cells Quantification and Phenotypic)

Arms and interventions

YTS109 cellExperimental

Subjects will receive YTS109 cell (1.5 E6 STAR +T cells/kg) once in this study.

Drugs: YTS109 cell

Sites

1 site in 1 country

  • The First Medical Center of Chinese PLA General HospitalBeijing, Beijing Municipality, China